drugset / Trial / NCT06395610

Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

NCT06395610

Phase 1 Completed 24 enrolled Chiesi Farmaceutici S.p.A.
Non-randomizedCrossoverOpen-labelOther

Summary

The objective of this study is to investigate the effect of the interaction of Erythromycin (CYP3A4/5 moderate inhibitor) on the pharmacokinetic of CHF6001 (CYP3A4/5 substrate) in Healthy Volunteers.

Timeline

Start
2024-03-28
Primary completion
2024-06-18
Completion
2024-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Erythromycin Small molecule Oral
Subject TRANIMILAST Small molecule